

23 Apr 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Merck & Co's Prometheus deal; Lilly's US mirikizumab rejection; Moderna and Merck's mRNA cancer vaccine shows promise; how SeaGen nearly lost its big pharma bidders; and Chinese firms move ahead with potential rivals to Enhertu.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 April 2023, including: [Merck & Co., Inc.](#)'s Prometheus deal; [Eli Lilly and Company](#)'s US mirikizumab rejection; [Moderna, Inc.](#) and Merck & Co., Inc.'s mRNA cancer vaccine shows promise; how [Seagen Inc.](#) nearly lost its big pharma bidders; and Chinese firms move ahead with potential rivals to Enhertu.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Merck Acquires Much Needed Diversification With \\$10.8bn Prometheus Buy](#)" - Scrip, 17 Apr, 2023.)

(Also see "[Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL](#)" - Scrip, 14 Apr, 2023.)

(Also see "[Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?](#)" - Scrip, 16 Apr, 2023.)

(Also see "[*Seagen, With Two Big Pharma Bidders, Nearly Lost Both*](#)" - Scrip, 17 Apr, 2023.)

(Also see "[*AACR: Chinese Pharma Firms Showcase Enhertu Fast-Followers*](#)" - Scrip, 18 Apr, 2023.)

[Click here to explore this interactive content online](#) ✎